StonvexLoading…
StonvexStonvexStonvexCore line items from TRU's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-22 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.29B | $1.25B | $4.58B | $3.40B | $2.24B |
Operating Income | Not available | $244.80M | $857.80M | $654.20M | $446.60M |
Net Income | Not available | $397.10M | $455.40M | $354.20M | $257.70M |
EPS (Diluted) | $1.15 | $2.04 | $2.32 | $1.80 | $1.31 |
Total Assets | Not available | $12.05B | $11.11B | $11.11B | $11.12B |
Total Liabilities | Not available | $7.13B | $6.57B | $6.53B | $6.49B |
Cash & Equivalents | Not available | $732.50M | $853.60M | $749.90M | $687.50M |
Free Cash Flow OCF − CapEx | Not available | $19.00M | $661.60M | $438.80M | $198.40M |
Shares Outstanding | Not available | 192.80M | 192.40M | 194.20M | 194.80M |